PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

SPRY4-IT1: A novel oncogenic long non-coding RNA in human cancers.

Abstract Long non-coding RNAs are classified as a kind of RNA, which are longer than 200 nucleotides in length and cannot be translated into proteins. Multiple studies have demonstrated that long non-coding RNAs are involved in various cellular processes, including proliferation, differentiation, cell death, and metastasis. Among numerous long non-coding RNAs, we focus on Sprouty4-Intron 1 (SPRY4-IT1), a well-known long non-coding RNA that is overexpressed in various kinds of tumor tissues and cell lines. Accumulating evidences show that SPRY4-IT1 was dysregulated in various cancers, including melanoma, breast cancer, esophageal squamous cell carcinoma, non-small cell lung cancer, gastric cancer, colon cancer, and hepatocellular carcinoma, and amplification of SPRY4-IT1 was associated with different clinicopathological features of cancer patients. Importantly, SPRY4-IT1 exerts important roles in tumor progression and metastasis. However, detailed molecular mechanisms of SPRY4-IT1 in cancer progression and metastasis were poorly understood. In this review, we have focused on the characteristics of SPRY4-IT1 and illustrated the biological function and mechanism of SPRY4-IT1 in cancer development.
PMID
Related Publications

Knockdown of long noncoding RNA SPRY4-IT1 suppresses glioma cell proliferation, metastasis and epithelial-mesenchymal transition.

Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.

Long noncoding RNA SPRY4-IT1 promotes esophageal squamous cell carcinoma cell proliferation, invasion, and epithelial-mesenchymal transition.

EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition.

Decreased long noncoding RNA SPRY4-IT1 contributing to gastric cancer cell metastasis partly via affecting epithelial-mesenchymal transition.

Authors

Mayor MeshTerms
Keywords

Long non-coding RNA

SPRY4-IT1

diagnostic biomarker

epithelial–mesenchymal transition

therapeutic target

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28651500
OWN - NLM
STAT- MEDLINE
DA  - 20170627
DCOM- 20170710
LR  - 20170713
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - SPRY4-IT1: A novel oncogenic long non-coding RNA in human cancers.
PG  - 1010428317711406
LID - 10.1177/1010428317711406 [doi]
AB  - Long non-coding RNAs are classified as a kind of RNA, which are longer than 200
      nucleotides in length and cannot be translated into proteins. Multiple studies
      have demonstrated that long non-coding RNAs are involved in various cellular
      processes, including proliferation, differentiation, cell death, and metastasis. 
      Among numerous long non-coding RNAs, we focus on Sprouty4-Intron 1 (SPRY4-IT1), a
      well-known long non-coding RNA that is overexpressed in various kinds of tumor
      tissues and cell lines. Accumulating evidences show that SPRY4-IT1 was
      dysregulated in various cancers, including melanoma, breast cancer, esophageal
      squamous cell carcinoma, non-small cell lung cancer, gastric cancer, colon
      cancer, and hepatocellular carcinoma, and amplification of SPRY4-IT1 was
      associated with different clinicopathological features of cancer patients.
      Importantly, SPRY4-IT1 exerts important roles in tumor progression and
      metastasis. However, detailed molecular mechanisms of SPRY4-IT1 in cancer
      progression and metastasis were poorly understood. In this review, we have
      focused on the characteristics of SPRY4-IT1 and illustrated the biological
      function and mechanism of SPRY4-IT1 in cancer development.
FAU - Li, Jianfa
AU  - Li J
AD  - 1 Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's
      Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, People's
      Republic of China.
AD  - 2 Shantou University Medical College, Shantou, People's Republic of China.
FAU - Chen, Yincong
AU  - Chen Y
AD  - 2 Shantou University Medical College, Shantou, People's Republic of China.
FAU - Chen, Zhicong
AU  - Chen Z
AD  - 1 Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's
      Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, People's
      Republic of China.
AD  - 2 Shantou University Medical College, Shantou, People's Republic of China.
FAU - He, Anbang
AU  - He A
AD  - 2 Shantou University Medical College, Shantou, People's Republic of China.
AD  - 3 Anhui Medical University, Hefei, People's Republic of China.
FAU - Xie, Haibiao
AU  - Xie H
AD  - 1 Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's
      Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, People's
      Republic of China.
AD  - 2 Shantou University Medical College, Shantou, People's Republic of China.
FAU - Zhang, Qiaoxiao
AU  - Zhang Q
AD  - 1 Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's
      Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, People's
      Republic of China.
FAU - Cai, Zhiming
AU  - Cai Z
AD  - 1 Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's
      Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, People's
      Republic of China.
AD  - 2 Shantou University Medical College, Shantou, People's Republic of China.
AD  - 3 Anhui Medical University, Hefei, People's Republic of China.
FAU - Liu, Yuchen
AU  - Liu Y
AD  - 1 Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's
      Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, People's
      Republic of China.
FAU - Huang, Weiren
AU  - Huang W
AD  - 1 Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's
      Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, People's
      Republic of China.
AD  - 2 Shantou University Medical College, Shantou, People's Republic of China.
AD  - 3 Anhui Medical University, Hefei, People's Republic of China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (long noncoding RNA SPRY4-IT1, human)
SB  - IM
MH  - Carcinogenesis/*genetics
MH  - Cell Proliferation/genetics
MH  - Epithelial-Mesenchymal Transition/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Neoplasm Metastasis
MH  - Neoplasms/*genetics
MH  - RNA, Long Noncoding/*genetics
OTO - NOTNLM
OT  - Long non-coding RNA
OT  - SPRY4-IT1
OT  - diagnostic biomarker
OT  - epithelial-mesenchymal transition
OT  - therapeutic target
EDAT- 2017/06/28 06:00
MHDA- 2017/07/14 06:00
CRDT- 2017/06/28 06:00
AID - 10.1177/1010428317711406 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317711406. doi: 10.1177/1010428317711406.